Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29815406 | 0.84 | PPARA (0.48) | FOLH1HTTKMT2ASLC1A1CA1 | |
| SCHEMBL12744032 | 0.82 | TSHR (0.56) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL5870182 | 0.81 | FOLH1 (0.58) | FOLH1HTTKMT2ASLC1A1CA1 | |
| SCHEMBL28779141 | 0.81 | CPA3 (0.57) | FOLH1CPA3MMP12 | |
| SCHEMBL23949886 | 0.80 | KMT2A (0.47) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL13405409 | 0.80 | KMT2A (0.47) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL13839195 | 0.80 | NPC1 (0.48) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL2308784 | 0.80 | HTT (0.46) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL3374459 | 0.80 | HTT (0.46) | HTTKMT2ASLC1A1CA1CA2 | |
| SCHEMBL28120493 | 0.80 | KMT2A (0.46) | HTTKMT2ACA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022161448-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-04 | — | — | WO | disclosed |